In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral ...
Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...
In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...
By Sriparna Roy and Bhanvi Satija (Reuters) -Viking Therapeutics shares reversed course to fall 8% on Monday as focus shifted ...
The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...
Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...
Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of ...
GZR18 is an investigational drug ... obese (BMI≥28 kg/m²) or overweight (BMI≥24 kg/m²) with at least one weight-related comorbidity and whose weight was poorly controlled by diet and exercise.
Viking Therapeutics Inc. (VKTX) on Sunday issued positive early results in the trial of its experimental obesity pill VK2735, reports ...
In the 48 mg Q2W GZR18 group, the proportions of participants achieving ... "Ascletis") announces topline results of its Phase I single ascending dos... Hanmi Unveils Novel Obesity Drug 'HM17321' : A ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback